New strategies in the treatment of human acute myelogenous leukemia; clinical and experimental studies
- Prosjektnummer
- 911400
- Ansvarlig person
- Øystein Bruserud
- Institusjon
- Universitetet i Bergen
- Prosjektkategori
- Forskningsprosjekt
- Helsekategori
- Blood
- Forskningsaktivitet
- 5. Treatment Developement
Immunogenic apoptosis in human acute myeloid leukemia (AML): primary human AML cells expose calreticulin and release heat shock protein (HSP) 70 and HSP90 during apoptosis.
Oncol Rep 2011 Jun;25(6):1549-56. Epub 2011 mar 22
PMID: 21431284
Combination of the histone deacetylase inhibitor valproic acid with oral hydroxyurea or 6-mercaptopurin can be safe and effective in patients with advanced acute myeloid leukaemia--a report of five cases.
Hematology 2010 Oct;15(5):338-43.
PMID: 20863429
Intensive chemotherapy for acute myeloid leukemia differentially affects circulating TC1, TH1, TH17 and TREG cells.
BMC Immunol 2010;11():38. Epub 2010 jul 9
PMID: 20618967
Targeting the angiopoietin (Ang)/Tie-2 pathway in the crosstalk between acute myeloid leukaemia and endothelial cells: studies of Tie-2 blocking antibodies, exogenous Ang-2 and inhibition of constitutive agonistic Ang-1 release.
Expert Opin Investig Drugs 2010 Feb;19(2):169-83.
PMID: 20050812
Therapeutic efficacy of platelet transfusion in patients with acute leukemia: an evaluation of methods.
Transfusion 2010 Apr;50(4):766-75. Epub 2009 des 18
PMID: 20030789
Untangling the intracellular signalling network in cancer--a strategy for data integration in acute myeloid leukaemia.
J Proteomics 2011 Mar;74(3):269-81. Epub 2010 nov 12
PMID: 21075225
Hypoxia increases HIF-1a expression and constitutive cytokine release by primary human acute myeloid leukaemia cells.
Eur Cytokine Netw 2010 Sep;21(3):154-64. Epub 2010 aug 20
PMID: 20729179
Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors: release profile and pharmacological modulation.
Eur J Haematol 2010 Mar;84(3):239-51. Epub 2009 nov 17
PMID: 19922462
Use of different DMSO concentrations for cryopreservation of autologous peripheral blood stem cell grafts does not have any major impact on levels of leukocyte- and platelet-derived soluble mediators.
Cytotherapy 2009;11(6):749-60.
PMID: 19878061
Heat shock protein 90 - a potential target in the treatment of human acute myelogenous leukemia.
Curr Cancer Drug Targets 2009 Sep;9(6):761-76.
PMID: 19754360
Long-term cryopreservation of autologous stem cell grafts: a clinical and experimental study of hematopoietic and immunocompetent cells.
Transfusion 2009 Apr. Epub 2009 apr 20
PMID: 19392777
The protein kinase C agonist PEP005 increases NF-kappaB expression, induces differentiation and increases constitutive chemokine release by primary acute myeloid leukaemia cells.
Br J Haematol 2009 Jun;145(6):761-74. Epub 2009 apr 20
PMID: 19388934
Connexins are active participants of hematopoietic stem cell regulation.
Stem Cells Dev 2009 Jul-Aug;18(6):807-12.
PMID: 19355839
Targeted therapy in acute myeloid leukaemia: current status and future directions.
Expert Opin Investig Drugs 2009 Apr;18(4):433-55.
PMID: 19335274
Genes of cell-cell interactions, chemotherapy detoxification and apoptosis are induced during chemotherapy of acute myeloid leukemia.
BMC Cancer 2009;9():77. Epub 2009 mar 5
PMID: 19265549
Primary human acute myeloid leukaemia cells increase the proliferation of microvascular endothelial cells through the release of soluble mediators.
Br J Haematol 2009 Jan;144(1):53-68. Epub 2008 okt 30
PMID: 19016730
A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and all-trans retinoic acid.
Leuk Res 2009 Jun;33(6):779-87. Epub 2008 nov 12
PMID: 19007987
Hematopoietic engraftment of dimethyl sulfoxide-depleted autologous peripheral blood progenitor cells.
Transfusion 2009 Feb;49(2):354-61. Epub 2008 okt 28
PMID: 18980622
Circulating T cells derived from acute leukemia patients with severe therapy-induced cytopenia express a wide range of chemokine receptors.
Hematology 2008;13(6):329-32.
PMID: 19055860
In vivo biological effects of ATRA in the treatment of AML.
Expert Opin Investig Drugs 2008 Nov;17(11):1623-33.
PMID: 18922099
In vitro induction of a dendritic cell phenotype in primary human acute myelogenous leukemia (AML) blasts alters the chemokine release profile and increases the levels of T cell chemotactic CCL17 and CCL22.
J Interferon Cytokine Res 2008 May;28(5):297-310.
PMID: 18547160
Review: genetic models of acute myeloid leukaemia.
Oncogene 2008 Jun;27(27):3765-79. Epub 2008 feb 11
PMID: 18264136
Platelet functions and clinical effects in acute myelogenous leukemia.
Thromb Haemost 2008 Jan;99(1):27-37.
PMID: 18217131
Abolition of stress-induced protein synthesis sensitizes leukemia cells to anthracycline-induced death.
Blood 2008 Mar;111(5):2866-77. Epub 2008 jan 8
PMID: 18182573
Release of angiopoietin-1 by primary human acute myelogenous leukemia cells is associated with mutations of nucleophosmin, increased by bone marrow stromal cells and possibly antagonized by high systemic angiopoietin-2 levels.
Leukemia 2008 Feb;22(2):287-93. Epub 2007 okt 18
PMID: 17943167
Nuclear factor-kB signaling: a contributor in leukemogenesis and a target for pharmacological intervention in human leukemia
Crit Rev Oncogenesis, 2009.
Angiogenic factors in human acute myeloid leukemia
- Disputert:
- april 2009
- Hovedveileder:
- Øystein Bruserud
Preparation and therapeutic use of peripheral blood apheresis products in hematologic malignancies
- Disputert:
- november 2009
- Hovedveileder:
- Øystein Bruserud
Preparation and clinical use of peripheral blood stem cell grafts
- Disputert:
- september 2009
- Hovedveileder:
- Øystein Bruserud
New strategies in the treatment of acute myeloid leukemia
- Disputert:
- april 2008
- Hovedveileder:
- Øystein Bruserud
The chemokine system in acute myelogenous leukemia
- Disputert:
- juni 2008
- Hovedveileder:
- Øystein Bruserud
eRapport er utarbeidet av Sølvi Lerfald og Reidar Thorstensen, Regionalt kompetansesenter for klinisk forskning, Helse Vest RHF, og videreutvikles av de fire RHF-ene i fellesskap, med støtte fra Helse Vest IKT
Alle henvendelser rettes til Faglig rapportering, Helse Vest